Skip to main content
Premium Trial:

Request an Annual Quote

Biogazelle Nabs $2.5M Investment to Develop Therapeutic RNA Targets

NEW YORK (GenomeWeb) — Biogazelle said today that it has received a €2 million ($2.5 million) investment from Qbic Arkiv Fund, Foundation Majoie, and SOFI (Spin-Off Financing Instrument).

Ghent, Belgium-based Biogazelle said that it will primarily use the investment to further develop its research on therapeutic RNA targets for specific cancer types and expand its commercial activities.

Biogazelle is a 2007 Ghent University spinout founded by CEO Jan Hellemans and CSO Jo Vandesompele. The company uses tools such as RNA sequencing, digital PCR, and its qbase+ software to provide gene expression analysis services.

"After a successful start period with an annual growth rate of 70 percent during which Biogazelle's qbase+ software was launched and a laboratory service was initiated, it was important to acquire additional funding to support the growth and internationalization of our commercial activities … and to start our own research programs," Hellemans said in a statement.

Vandesompele added in a statement that the company plans to "prioritize top candidate RNA targets, followed by high-throughput testing in our lab using anti-sense silencing technology."

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.